What is Bristol-Myers Squibb's market cap?

Bristol-Myers Squibb (BMY) has a market capitalization of $117.50B and trades on NYSE.

What is Bristol-Myers Squibb's revenue and profitability?

Bristol-Myers Squibb generated $48.5B in trailing twelve-month revenue with net income of $7.3B, representing a net margin of 15.0%. Gross margin stands at 70.5%, with free cash flow of $11.9B. These figures are based on the Q1 2026 filing.

Who are Bristol-Myers Squibb's competitors?

Bristol-Myers Squibb's key competitors include Merck & Co., Johnson & Johnson, Novartis AG, and others. These companies compete in similar markets and product categories.

Who does Bristol-Myers Squibb partner with?

Bristol-Myers Squibb's notable partners include Pfizer Inc..

What subsidiaries does Bristol-Myers Squibb have?

Bristol-Myers Squibb's subsidiaries include Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and others.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in United States of America and employs approximately 34,100 people. It has been publicly traded since 1952.

Bristol-Myers Squibb

BMY

Bristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases.

Market cap

$117.5B+23.1%

Revenue$48.5B+1.8%

Net income$7.3B+36.1%

Free cash flow$11.9B-9.0%

EPS (diluted)$3.56+35.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$11.5BBeat by $561.6M EPS$1.58Beat by $0.16

Read the full report

Next report

Jul 30, 2026 (In 2 weeks)

Revenue estimate$11.7B

EPS estimate$1.61

Financials

Q1 2026

Income statement

See full

Revenue$11.5B+2.6%

Gross profit$8.1B-1.2%

Net income$2.7B+9.0%

EPS (diluted)$1.31+9.2%

Balance sheet

See full

Cash & equivalents$9.6B-12.0%

Total debt$44.7B-10.5%

Total equity$20.1B+15.4%

Total assets$86.5B-6.4%

Cash flow

See full

Operating cash flow$1.1B-43.5%

CapEx$347.0M+33.5%

Free cash flow$757.0M-55.3%

Valuation & ratios

Valuation

See full

Market cap$117.5B+23.1%

Enterprise value$152.59B+15.4%

P/E16.2×-3.0×

P/S2.4×+0.4×

Profitability

See full

Gross margin70.5%0.0pp

Net margin15%+3.8pp

FCF margin24.6%-2.9pp

Returns & leverage

See full

Return on equity38.8%+7.3pp

Debt / equity2.2×-0.6×

Current ratio1.4×+0.1×

Segments

By product

See full

Eliquis$4.1B+16.0%

Opdivo$2.1B-5.3%

Orencia$818.0M+6.2%

Yervoy$651.0M+4.3%

Other Growth products$581.0M+14.6%

By geography

See full

International$3.4B—

Other$257.0M+17.9%

Competitors

By market cap

Johnson & Johnson$634.06B+68.9%

AbbVie$446.54B+33.6%

Merck & Co.$311.17B+53.1%

Pfizer$137.07B-5.0%

Bristol-Myers Squibb$117.50B+23.1%

Roivant Sciences$26.0B+247%

Opko Health$1.1B-1.3%

Theravance Biopharma$881.1M+58.0%

By revenue growth

Theravance Biopharma+68.2%

AbbVie+9.5%

Johnson & Johnson+7.9%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

Pfizer+1.4%

Opko Health-15.7%

Roivant Sciences-71.6%

By net margin

Theravance Biopharma104.34%+194pp

Johnson & Johnson21.83%-2.6pp

Pfizer15.65%+6.3pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

Opko Health-36.64%-31.0pp

Roivant Sciences-6,079.94%—

Profile

Bristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases. The company combines the scale of a major pharmaceutical firm with the innovation-driven focus of biotechnology to address high-need therapeutic areas including oncology, hematology, immunology, and cardiovascular health.

Competitive position

A leading global biopharmaceutical entity with a dominant presence in oncology and cardiovascular medicine, characterized by high R&D investment and strategic acquisitions.

GeographiesUnited States, Switzerland, Ireland, Netherlands, Global

Customer segmentsHealthcare providers, Pharmaceutical distributors, Public health systems

Business modelR&D-based manufacturing, Licensing and Royalties, Direct-to-institution sales

SuppliersRaw chemical suppliers, Contract research organizations, Academic research institutions, Biotech licensing partners

CustomersDrug wholesalers, Retail pharmacies, Medical centers, Government health programs

CountryUnited States of America

Listed1952

Employees34.1K

CEOChristopher S. Boerner

SectorHealthcare

IndustryDrug Manufacturers - General

Websitebms.com

FilingsSEC EDGAR

Ask your AI about Bristol-Myers Squibb.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bristol-Myers Squibb's market cap?: Bristol-Myers Squibb (BMY) has a market capitalization of $117.50B and trades on NYSE.
What is Bristol-Myers Squibb's revenue and profitability?: Bristol-Myers Squibb generated $48.5B in trailing twelve-month revenue with net income of $7.3B, representing a net margin of 15.0%. Gross margin stands at 70.5%, with free cash flow of $11.9B. These figures are based on the Q1 2026 filing.
Who are Bristol-Myers Squibb's competitors?: Bristol-Myers Squibb's key competitors include Merck & Co., Johnson & Johnson, Novartis AG, and others. These companies compete in similar markets and product categories.
Who does Bristol-Myers Squibb partner with?: Bristol-Myers Squibb's notable partners include Pfizer Inc..
What subsidiaries does Bristol-Myers Squibb have?: Bristol-Myers Squibb's subsidiaries include Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and others.
Where is Bristol-Myers Squibb headquartered?: Bristol-Myers Squibb is headquartered in United States of America and employs approximately 34,100 people. It has been publicly traded since 1952.